Wednesday, November 25, 2009, 8:37am EST - Canadian Markets open in 53 minutes.
To create a watchlist or portfolio of shares, Sign-in or Register

Neurocrine Biosciences Inc. (NBIX)

 On Nov 24: 2.17 USD   0.00 (0.00%)  
MORE ON NBIX
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
Neurocrine Biosciences, Inc. (NasdaqNM:NBIX) Delayed quote dataEdit
Last Trade: 2.17 USD
Trade Time: Nov 24
Change: 0.00 (0.00%)
Prev Close: 2.17
Open: N/A
Bid: 2.10 x 1000
Ask: 2.50 x 5400
1y Target Est: 6.29
Day's Range: N/A - N/A
52wk Range: 2.00 - 4.25
Volume: 0
Avg Vol (3m): 154,088
Market Cap: 85.08M
P/E (ttm): N/A
EPS (ttm): -2.48
Div & Yield: N/A (N/A%)
Neurocrine Biosciences Inc. (NBIX)
1d  5d  3m  6m  1y  2y  5y  max 
Free Annual Reports
 Add NBIX to Portfolio   Download Data

HEADLINES
• Neurocrine Biosciences to Present at the 21st Annual Piper Jaffray Health Care Conference
PRNewswire (Tue 12:00pm)
• NEUROCRINE BIOSCIENCES INC Financials
EDGAR Online Financials (Wed, Nov 4)
• NEUROCRINE BIOSCIENCES INC Files SEC form 10-Q, Quarterly Report
EDGAR Online (Thu, Oct 29)
• Neurocrine Biosciences, Inc. Q3 2009 Earnings Conference Call
at Seeking Alpha (Thu, Oct 29)
• NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
EDGAR Online (Wed, Oct 28)
• Neurocrine Biosciences Reports Third Quarter 2009 Results
PRNewswire (Wed, Oct 28)
• Q3 2009 Neurocrine Biosciences, Inc. Earnings Release - After Market Close
CCBN (Wed, Oct 28)
• Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2009 Financial Results CONFERENCE CALL AND WEBCAST THURSDAY, OC
PRNewswire (Fri, Oct 23)
• NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Entry into a Material Definitive Agreement
EDGAR Online (Thu, Oct 1)
• Neurocrine Biosciences Amends Corporate Headquarters Lease REDUCES LEASING OBLIGATION BY $27 MILLION
PRNewswire (Thu, Oct 1)
More Headlines for NBIX...
ANALYST
EPS Est (next year) (Dec-07) : -2.87
EPS Est (in 2 years) (Dec-08) : -2.63
Avg Rec (current)*: 3.2
PEG Ratio: N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
Neurocrine Biosciences, Inc. engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States.

Full Company Profile

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices